ADA and severe combined immunodeficiency: Owing to the broad potential and guaranteed physiological activities, gene therapy has been increasingly applied for more than 3 decades, and the first clinical trial of adenosine deaminase (ADA) gene therapy for the treatment of severe combined immunodeficiency (SCID) was in 1990 6.